Bevacizumab and Metronomic Chemotherapy Plus Diet and Exercise Evaluated for Breast Cancer Recurrence
Background
For patients with breast cancer who have residual disease after preoperative chemotherapy, the risk of recurrence remains high. Current standard-of-care often involves observation, which may not be sufficient for all patients. This study explores whether adding bevacizumab, an anti-angiogenic monoclonal antibody targeting VEGF, alongside metronomic chemotherapy and lifestyle interventions, can improve outcomes. The rationale is to target residual disease and potentially enhance systemic therapy efficacy through synergistic mechanisms and improved patient health.
Study Design
This Phase 2/3 randomized clinical trial (NCT02126449) enrolled 131 participants with residual breast cancer after preoperative chemotherapy and surgery. Participants were assigned to one of four arms: (1) Diet Intervention, (2) Diet and Exercise Intervention, (3) Bevacizumab (dose not specified in abstract), cyclophosphamide (metronomic), methotrexate (metronomic) and Diet Intervention, or (4) Bevacizumab, metronomic chemotherapy, Diet and Exercise Intervention. The primary endpoint is to determine the difference in breast cancer recurrence rates between these post-neoadjuvant strategies.
Results
This study is designed to evaluate whether additional treatment with bevacizumab and metronomic chemotherapy (cyclophosphamide, methotrexate) significantly reduces the chance of breast cancer recurrence compared to standard observation. The trial also aims to quantify the potential benefits of a combined diet and exercise intervention versus a diet intervention alone on recurrence rates. Specific numerical findings on efficacy or safety are not yet available, as this abstract describes the study protocol and objectives.
Key Findings
- Study aims to determine if bevacizumab + metronomic chemotherapy reduces breast cancer recurrence.
- Evaluates additional benefits of exercise alongside dietary intervention post-chemotherapy.
- Compares four treatment arms: Diet, Diet+Exercise, Bevacizumab+Chemo+Diet, Bevacizumab+Chemo+Diet+Exercise.
Why It Matters
This trial addresses a critical unmet need for patients with residual breast cancer after initial chemotherapy, where recurrence risk is elevated. If successful, this study could establish a new standard of care beyond observation, integrating targeted biological therapy and metronomic chemotherapy with lifestyle interventions. The findings could inform future clinical protocols, potentially leading to improved long-term outcomes and a more personalized approach to adjuvant therapy. It highlights the potential of combining pharmacological and non-pharmacological strategies to reduce disease burden.
breast-cancer
bevacizumab
metronomic-chemotherapy
diet
exercise
recurrence